Eigenmann & Veronelli announces the acquisition of IMEA Technologies to accelerate growth in the MEA region
4.9.2023 11:00:00 EEST | Business Wire | Press release
Eigenmann & Veronelli S.p.A., a leading distributor in the specialty chemicals and food ingredients industry, today announced that it has acquired 100% of IMEA Technologies FZC, a regional distribution company of specialty chemicals with a focus on the industrial market, based in the United Arab Emirates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904875181/en/
Eigenmann & Veronelli announces the acquisition of IMEA Technologies to accelerate growth in the MEA region. (Photo: Business Wire)
The acquisition represents an excellent fit with E&V’s existing operations and a strategic commercial expansion in the Middle East and Africa region, in addition to the Far East and Indian markets, reinforcing its international footprint to consolidate its compelling portfolio and execute its growth strategy.
IMEA Technologies was founded in 2011, in Sharjah (U.A.E.), and offers a wide range of products, mainly industrial, such as emulsion polymers for industries, paints, plastic, inks, water treatment, sealants & adhesives, oil & gas, and construction, as well as cosmetic & cleaning applications.
Headquartered in Sharjah, with offices & warehouses in U.A.E., the Company ensures the full coverage of the MEA region in addition to the Far East and Indian markets. In 2022, IMEA Technologies generated revenues of approximately AED 68.5M (ca. EUR 17.7 million).
IMEA Technologies, as part of the E&V Group, will be led by its present management line-up and staff retaining its well-established name.
Gabriele Bonomi, Chief Executive Officer of the E&V Group, comments:
“In line with our strategic vision to be an established international solutions provider, we are delighted to welcome IMEA Technologies to the E&V Group. This acquisition strengthens our international footprint and allows us to offer a truly compelling value proposition to both principals and customers.”
Ayoob Chekkintakath, Executive Director of IMEA Technologies, adds:
“Becoming part of E&V, a key international market player, marks a milestone in our company’s evolution. We share a similar vision and culture, and I am confident that IMEA Technologies will continue to thrive as part of the E&V Group, continuing its long-term relationships with key suppliers and customers.”
ABOUT EIGENMANN & VERONELLI S.p.A.
Eigenmann & Veronelli is an international solutions provider in the specialty chemicals and food ingredients industry with a direct presence in 4 countries and a commercial reach in more than 30. Headquartered in Rho, Milan, Italy, E&V is synonymous with effectiveness and efficiency, combining local market knowledge with international chemical innovations. In 2022 the E&V Group generated a consolidated turnover of EUR 417 M with 340 employees.
To find out more about E&V, please visit: www.eigver.com
ABOUT IMEA TECHNOLOGIES FZC
IMEA Technologies is a regional distributor of specialty chemicals, specialized in industrial market, such as emulsion polymers for industries, paints, plastic, inks, water treatment, sealants & adhesives, oil & gas, and construction, as well as cosmetics & cleaning applications. Headquartered in Saif Zone, Sharjah (U.A.E.), with offices and warehouses in U.A.E. IMEA Tech. posted a consolidated turnover of EUR 17.7 M in 2022.
To find out more, please visit: www.imeatech.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904875181/en/
Contact information
Press Contact
Federica Urso
Group Corporate Communication Manager, E&V S.p.A
mediarelations@eigver.it - +39 338.7295116
Commercial Contact
Ayoob Chekkintakath
Executive Director, IMEA TECHNOLOGIES FZC
info@imeatech.com - +971 6 5574800
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom